NCT05590559

Brief Summary

The objective of this study is to assess the non-inferiority of analgesic efficacy of ESP vs PVB for patients undergoing unilateral mastectomy followed by immediate reconstruction.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2021

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

October 18, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 21, 2022

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

October 21, 2022

Status Verified

October 1, 2022

Enrollment Period

1.6 years

First QC Date

October 18, 2022

Last Update Submit

October 20, 2022

Conditions

Keywords

Ultrasound-guided erector spinae plane blockparavertebral block

Outcome Measures

Primary Outcomes (2)

  • Mean difference of highest numerical rating score (NRS - a linear 11 point scale for self-reported pain) during admission in the recovery room

    1 day

  • Difference in the ratio of the means of cumulative opioid dose (administered during admission in the recovery room)

    1 day

Secondary Outcomes (7)

  • Success rate as defined by satisfactory spread of local anaesthetic agents on ultrasound

    1 month

  • Ease of procedure (self-reported by anaesthetist on scale of 1-5)

    1 month

  • Total opioid dose administered on day 0 and on day 1 (iv, subcutaneous or oral - converted to morphine equivalent dose (MEQ)

    1 day after dose administration

  • Highest pain score on day 0 and 1

    1 day

  • Time to readiness for discharge from the recovery room

    1 day

  • +2 more secondary outcomes

Study Arms (2)

paravertebral block

ACTIVE COMPARATOR
Drug: Morphine

Ultrasound-guided erector spinae plane block

EXPERIMENTAL
Other: Ultrasound-guided erector spinae plane block

Interventions

Opiates

paravertebral block

PVB

Ultrasound-guided erector spinae plane block

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailsadult female patients
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients (18 years of age or older)
  • ASA I-III
  • Patients scheduled for elective unilateral mastectomy followed by direct reconstruction
  • Ability to give written and oral informed consent

You may not qualify if:

  • Patient refusal
  • Non-elective surgery
  • Any contraindication to paravertebral block (including bleeding diathesis, coagulopathy, severe pulmonary disease )
  • Allergy to amide-linked local anesthetics
  • Cardiac conductivity disorders (e:g: 2nd and 3rd AV-block)
  • Severe spinal malformations or history of extensive spine surgery - A history of spinal cord injury
  • Known psychiatric disorder
  • Chronic pain patients or patients already using opioids pre-operatively
  • Infection of the skin at the site of needle puncture area - Inability to give oral and written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NKI-AvL

Amsterdam, North Holland, 1066CX, Netherlands

RECRUITING

MeSH Terms

Interventions

Morphine

Intervention Hierarchy (Ancestors)

Morphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Central Study Contacts

Sandra Broens, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 18, 2022

First Posted

October 21, 2022

Study Start

June 1, 2021

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

October 21, 2022

Record last verified: 2022-10

Locations